Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
132 USD | +0.15% | +6.74% | +21.03% |
Mar. 28 | Robert Davis, Merck CEO: Another obesity drug? | MT |
Mar. 28 | Merck: new indication approved for Keytruda in Europe | CF |
Financials (USD)
Sales 2024 * | 63.76B | Sales 2025 * | 68.03B | Capitalization | 334B |
---|---|---|---|---|---|
Net income 2024 * | 19.74B | Net income 2025 * | 22.12B | EV / Sales 2024 * | 5.55 x |
Net Debt 2024 * | 19.56B | Net Debt 2025 * | 7.5B | EV / Sales 2025 * | 5.02 x |
P/E ratio 2024 * |
16.8
x | P/E ratio 2025 * |
14.6
x | Employees | 71,000 |
Yield 2024 * |
2.36% | Yield 2025 * |
2.49% | Free-Float | 70.71% |
Latest transcript on Merck & Co., Inc.
1 day | +0.15% | ||
1 week | +6.74% | ||
Current month | +3.78% | ||
1 month | +2.93% | ||
3 months | +21.31% | ||
6 months | +26.51% | ||
Current year | +21.03% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
Director of Finance/CFO | 55 | 89-12-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 07-11-26 |
Pamela Craig
BRD | Director/Board Member | 67 | 15-08-31 |
Inge Thulin
BRD | Director/Board Member | 69 | 18-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
14.34% | 227 M€ | +6.28% | - | |
5.61% | 18 M€ | +6.77% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 132 | +0.15% | 10,189,650 |
24-03-27 | 131.8 | +4.96% | 16,061,581 |
24-03-26 | 125.5 | +0.17% | 8,864,402 |
24-03-25 | 125.3 | +1.18% | 7,605,755 |
24-03-22 | 123.8 | +0.19% | 7,022,502 |
Delayed Quote Nyse, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.03% | 334B | |
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+17.51% | 322B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B | |
-1.28% | 152B |